MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-06-2026
Kamada Ltd. Revenue 2011-2026 | KMDA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Kamada Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 M | 161 M | 143 M | 129 M | 104 M | 133 M | 127 M | 114 M | 103 M | 77.5 M | 69.9 M | 71.1 M | 70.6 M | 72.7 M | 55.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 180 M | 55.9 M | 107 M |
Quarterly Revenue Kamada Ltd.
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 M | 47 M | 44.8 M | 44 M | 161 M | 41.7 M | 42.5 M | 37.7 K | 143 M | 37.9 K | 37.4 M | 30.7 M | - | - | - | - | - | 23 M | - | - | - | 35.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 180 M | 37.7 K | 59.3 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
257 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
71.5 K | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 16.89 | -2.37 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
6 M | $ 2.85 | -5.94 % | $ 266 M |  Israel |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.58 | -3.37 % | $ 185 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
AstraZeneca PLC
AZN
|
58.7 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 7.46 | -4.73 % | $ 204 M | Israel |
 |
Eton Pharmaceuticals
ETON
|
80 M | $ 29.73 | -0.77 % | $ 800 M | USA |
 |
Exelixis
EXEL
|
2.32 B | $ 50.09 | -1.98 % | $ 13.6 B | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Fortress Biotech
FBIO
|
63.3 M | $ 2.47 | 7.39 % | $ 68.9 M | USA |
 |
Forte Biosciences
FBRX
|
18 M | $ 22.53 | -5.97 % | $ 292 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
44.6 M | $ 9.51 | 2.92 % | $ 272 M | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 4.03 | -8.52 % | $ 1.2 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.57 | -1.26 % | $ 418 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
482 M | $ 88.94 | -3.32 % | $ 21.5 B | Germany |
 |
Gilead Sciences
GILD
|
29.4 B | $ 129.56 | -1.9 % | $ 161 B | USA |
 |
Genmab A/S
GMAB
|
10.1 B | $ 26.79 | -0.41 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 3.36 | -5.62 % | $ 5.53 M | Israel |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 7.67 | -1.6 % | $ 5.21 B |  Spain |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
403 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 21.66 | 0.42 % | $ 2.76 B | USA |